Detalhe da pesquisa
1.
A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges.
Front Pharmacol
; 12: 666405, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34867312
2.
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications.
Expert Rev Pharmacoecon Outcomes Res
; 21(4): 527-540, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33535841
3.
Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab.
Appl Health Econ Health Policy
; 18(1): 5-16, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31696433
4.
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.
Front Pharmacol
; 11: 591134, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33519450
5.
Where is industry getting it wrong? A review of quality concerns raised at Day 120 by the Committee For Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions for Chemical Entity Medicinal Products.
J Pharm Pharm Sci
; 12(2): 181-98, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19732496
6.
Proposal for a regulation on health technology assessment in Europe - opinions of policy makers, payers and academics from the field of HTA.
Expert Rev Pharmacoecon Outcomes Res
; 19(3): 251-261, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30696372
7.
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.
Front Public Health
; 6: 328, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30568938
8.
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.
Pharmacoeconomics
; 35(12): 1271-1285, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-28836222
9.
Policies for biosimilar uptake in Europe: An overview.
PLoS One
; 12(12): e0190147, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29284064
10.
Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries.
Front Pharmacol
; 8: 942, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29403372
11.
Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.
Front Pharmacol
; 8: 497, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28878667
12.
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.
Front Pharmacol
; 7: 305, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27733828
13.
Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.
Front Pharmacol
; 7: 197, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27516740